论文部分内容阅读
在为大多数糖尿病患者制定个体化的治疗方案时,临床医生往往偏爱在生活方式干预的基础上首选二甲双胍。目前,随着对2型糖尿病理解的深入,一系列新的降糖药涌现出来,使得2型糖尿病管理变得更加复杂。最近,由美国糖尿病协会、美国临床内分泌学家协会、美国内分泌学会和欧洲糖尿病学会出版的糖尿病防治指南恰恰突出了这一点。
When developing a personalized treatment for most people with diabetes, clinicians tend to prefer metformin over lifestyle interventions. With the current understanding of type 2 diabetes, a new set of hypoglycemic agents has emerged that have made management of type 2 diabetes more complicated. Recently, this guideline on diabetes prevention published by the American Diabetes Association, the American Society of Clinical Endocrinologists, the American Society of Endocrinology, and the European Diabetes Society highlights this point.